CAI · Health care(services-medical laboratories) · 4 years of annual accounts filed with the SEC · latest fiscal year ended 2025-12-31
Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›
Caris Life Sciences, Inc. reported revenue of $812.0 million in fiscal 2025. On the accounting screens, it passes 6 of 8 Piotroski tests, its Altman Z'' of -0.93 is in the distress zone and its Beneish M-score is below the -1.78 line; 1 of the six cross-checks between its statements fires.
Revenue, fiscal 2025812.0M
Operating margin5.6%gross margin —
Return on invested capital4.7%8.4% on average over 2 years
Free cash flow after stock pay-3.1M-0.4% of revenue
Net debt ÷ EBITDANet cash417.3M more cash than debt
Piotroski F-score6/8tests of improvement passed
Share counts are in today's shares. The SEC's filings restate only recent years after a split, so these jumps were read as splits and the older years scaled to match — otherwise per-share figures would compare different units:
5-for-1 before fiscal 2025.
Is it growing?
Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.
RevenueOperating income
-0.5B00.5B1.0B
2022
2023Revenue 306.1MOperating income -319.6M
2024Revenue 412.3MOperating income -257.1M
2025Revenue 812.0MOperating income 45.1M
2022202320242025
Does it earn more than its capital costs?
Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.
Needs a cost of capital, which comes from the valuation below.
Return on equity
-11.8%
Return on assets
-6.0%
Asset turnover
0.72×
Research & development
12.5% of revenue
Overheads (SG&A)
27.7% of revenue
Is the profit cash, and where does the cash go?
Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.
Net incomeFree cash flowAfter stock-based pay
-400M-200M0200M
2022
2023Net income -341.4MFree cash flow -298.4MAfter stock-based pay -313.7M
2024Net income -281.9MFree cash flow -253.6MAfter stock-based pay -272.3M
2025Net income -68.1MFree cash flow 66.9MAfter stock-based pay -3.1M
2022202320242025
Per share
Earnings per shareFree cash flow per shareDividend per share
-$2-$1$0$1
2022
2023Earnings per share $-1.95Free cash flow per share $-1.71
2024Earnings per share $-1.59Free cash flow per share $-1.43
2025Earnings per share $-0.41Free cash flow per share $0.40
2022202320242025
Shares outstanding
Diluted shares
165M170M175M180M
2022
2023Diluted shares 174.7M
2024Diluted shares 177.5M
2025Diluted shares 167.2M
2022202320242025
Debt and liquidity
Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.
Net debt
-600M-400M-200M0200M400M
2022
2023
2024Net debt 315.6M
2025Net debt -417.3M
2022202320242025
Net debt ÷ EBITDA
-6.2×
Interest coverage
1× operating income ÷ interest
Current ratio
7.85 current assets ÷ current liabilities
Cash conversion cycle
— collects in 50d
Three classic screens of the accounts
Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.
Piotroski F-score
Is the business improving? Nine yes-or-no tests, this year against last.
6of 8 tests passed
✕ProfitableReturn on assets above zerofailed
✓Cash from operationsOperating cash flow above zeropassed
✓Profitability improvedReturn on assets higher than a year beforepassed
✓Profit backed by cashOperating cash flow above net income (low accruals)passed
✓Less long-term debtLong-term debt as a share of assets fellpassed
✓More liquidCurrent ratio higher than a year beforepassed
✓No new sharesShare count did not growpassed
–Better gross marginGross margin higher than a year before — not reportedno data
✕Sells more per assetAsset turnover higher than a year beforefailed
Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.
Altman Z''-score
Does the balance sheet look like those of companies that went bankrupt?
-0.93distress zone
1.12.6
Working capital ÷ assets 0.77 × 6.56+5.07
Retained earnings ÷ assets -2.26 × 3.26-7.38
Operating income ÷ assets 0.04 × 6.72+0.27
Equity ÷ liabilities 1.05 × 1.05+1.11
Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.
Beneish M-score
Do the accounts resemble those of companies that manipulated their earnings?
-2.49below the -1.78 line
-1.78
Receivables vs sales 0.65+0.59
Gross margin slipping 1.00 (not reported, set to 1)+0.53
Soft assets 0.33+0.13
Sales growth 1.97+1.76
Slower depreciation 1.59+0.18
Overheads vs sales 0.67-0.12
Profit not in cash -0.13-0.63
Leverage rising 0.32-0.10
Where it misleads: fast growth and acquisitions. Sales growth carries a heavy weight, so a company growing 50% a year scores like a suspect without having done anything. It is a screen from a 1999 study, not an accusation.
Where the statements disagree
Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.
The effective tax rate is -0.0%.
Benign
A favourable geographic mix, or legitimate tax credits.
Worrying
Not sustainable; projecting it forward inflates the valuation.
What is it worth, under which assumptions?
A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.
With a free cash flow margin at or below zero in year ten, the business never generates cash for its owners and a DCF says nothing useful. Set a positive margin for year ten to see what it would take.
What it has filed lately
The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.
Every Form 4 filed in the last twelve months, read line by line: 6 filings by 6 people. Open-market purchases and sales are counted apart from awards, option exercises and shares withheld for taxes.
Bought on the open market—none in the period
Sold on the open market$27.2M5 sale(s) by 3 insider(s)
Under pre-arranged plans0%of the sales followed a 10b5-1 plan set months earlier
A Form 4 says what happened, when, how many shares and at what price. It does not say why: a sale can be diversification, a tax bill or a plan fixed months earlier, and an award is pay, not a purchase. Nothing here is a reason to buy or sell anything.
Which large funds report holding it
From the Form 13F of the 28 institutions followed on this site, as of the end of their last reported quarter. A 13F is filed up to 45 days later and shows only long positions in US-listed shares.
Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.
